Archive - March 2022
FDA decisions to watch
FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster
Positive results for Cerevance’s Parkinson’s drug
Sanofi and IGM Biosciences agree on deal potentially worth over $6bn
Mission Therapeutics launches clinical trial for kidney disease therapy
Caffeine Could Help Treat Some ADHD Symptoms: Study
Ivermectin For COVID-19: Large Study Sets The Record Straight On Horse Dewormer
ViiV Healthcare Announces US FDA Approval of Triumeq PD, the First Dispersible Single Tablet Regimen Containing Dolutegravir, a Once-Daily Treatment for Children Living with HIV